Crescita Therapeutics Inc (CTX) - Total Liabilities
Based on the latest financial reports, Crescita Therapeutics Inc (CTX) has total liabilities worth CA$4.75 Million CAD (≈ $3.44 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Crescita Therapeutics Inc (CTX) long-term investment share to see how much of total assets are deployed in long-term investments.
Crescita Therapeutics Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Crescita Therapeutics Inc (CTX) total assets.
Crescita Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Crescita Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
In8bio Inc
NASDAQ:INAB
|
USA | $3.38 Million |
|
Juggernaut Exploration Ltd
V:JUGR
|
Canada | CA$4.43 Million |
|
Perfect Moment Ltd.
NYSE MKT:PMNT
|
USA | $12.74 Million |
|
DevPort AB (publ)
ST:DEVP-B
|
Sweden | Skr120.96 Million |
|
K-Tig Ltd
AU:KTG
|
Australia | AU$4.49 Million |
|
Noviqtech Ltd
AU:NVQ
|
Australia | AU$1.38 Million |
|
Aalborg Boldspilklub A/S
CO:AAB
|
Denmark | Dkr65.15 Million |
|
Plurilock Security Inc
V:PLUR
|
Canada | CA$31.32 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Crescita Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CTX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crescita Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crescita Therapeutics Inc (2014–2025)
The table below shows the annual total liabilities of Crescita Therapeutics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$4.75 Million ≈ $3.44 Million |
-20.09% |
| 2024-12-31 | CA$5.95 Million ≈ $4.30 Million |
+2.96% |
| 2023-12-31 | CA$5.78 Million ≈ $4.18 Million |
-21.82% |
| 2022-12-31 | CA$7.39 Million ≈ $5.34 Million |
-12.02% |
| 2021-12-31 | CA$8.40 Million ≈ $6.07 Million |
+47.37% |
| 2020-12-31 | CA$5.70 Million ≈ $4.12 Million |
-0.54% |
| 2019-12-31 | CA$5.73 Million ≈ $4.14 Million |
-33.06% |
| 2018-12-31 | CA$8.56 Million ≈ $6.19 Million |
-9.52% |
| 2017-12-31 | CA$9.46 Million ≈ $6.84 Million |
-41.65% |
| 2016-12-31 | CA$16.21 Million ≈ $11.73 Million |
+255.95% |
| 2015-12-31 | CA$4.55 Million ≈ $3.29 Million |
+21.86% |
| 2014-12-31 | CA$3.74 Million ≈ $2.70 Million |
-- |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more